EGFR and lung cancer: In Palbociclib resistant lung cancer cells, an increased activation of several receptor kinases was observed, such as epidermal growth factor receptor (EGFR), ephrin type-A receptor 1/2 (EphA1/2) and fibroblast growth factor receptor (FGFR) (42).